No Data
No Data
Is being included in medical insurance a lifesaving straw? Shanghai Yizhong's core products cannot enter hospitals, investors inquire about the progress of national talks | Direct hitting earnings conference
①Due to the closure of the self-funded pharmacy in the core hospital, Shanghai Yizhong's self-paid product paclitaxel micelles, which are not included in medical insurance, cannot be admitted to the hospital, impacting its performance in the first half of the year. ②Shanghai Yizhong is preparing for the paclitaxel micelles to participate in this year's medical insurance negotiations. In response to this matter, the chairman stated that the national medical insurance negotiation progress for paclitaxel micelles is proceeding normally, and the final negotiation result will be announced in subsequent disclosures.
Yizhong Pharmaceutical Gets Nod For Pancreatic Cancer Drug Trial
Shanghai Yizhong (688091.SH): Paclitaxel polymer micelle for injection approved for clinical trials.
Shanghai Yizhong (688091.SH) issued an announcement, recently learned from the State Pharmaceutical Supervision and Administration Bureau website...
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) 26% Price Boost Is Out Of Tune With Earnings
Shanghai Yizhong (688091.SH): repurchased 0.0361 million shares of the company's stock
On September 4th, Gelonhui announced that as of August 30, 2024, the company repurchased a total of 36,118 shares of the company's stock through the Shanghai Stock Exchange trading system by centralized auction trading, accounting for 0.0176% of the company's current total share capital of 205,759,840 shares. The highest price of the repurchase transaction was 26.66 yuan/share, the lowest price was 26.11 yuan/share, and the total amount paid was RMB 956,228.66 (excluding transaction fees).
Shanghai Yizhong (688091.SH): 54.7131 million shares of restricted shares will be listed for trading on September 10.
Shanghai Yizhong (688091.SH) announced that the restricted shares to be listed and traded this time are part of the first issuance of restricted...
No Data
No Data